Statera Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Operating Revenue	2.2	-	-	-	-
Other Revenue	1.49	1.49	-	-	-
Revenue	3.69	1.49	-	-	-
Revenue Growth (YoY)	1459.14%	-	-	-	-
Cost of Revenue	1.1	0.49	-	-	-
Gross Profit	2.59	1	-	-	-
Selling, General & Admin	13.92	20.41	4.94	2.41	5.78
Research & Development	9.81	11.83	5.26	0.59	2.14
Operating Expenses	23.73	32.24	10.2	3	7.92
Operating Income	-21.14	-31.24	-10.2	-3	-7.92
Interest Expense	-1.69	-1.29	-0.13	-0.12	-0.06
Other Non Operating Income (Expenses)	-1.28	0.15	-1	-	-0.34
EBT Excluding Unusual Items	-24.11	-32.38	-11.33	-3.13	-8.32
Merger & Restructuring Charges	-0.8	-0.8	-0.3	-	-
Impairment of Goodwill	-67.71	-67.71	-	-	-
Gain (Loss) on Sale of Assets	-0.05	-	-	-	-
Asset Writedown	0.1	0.1	-	-	-
Legal Settlements	-0.03	-2.13	-	-	-
Other Unusual Items	0.73	1.03	-0.46	-0.1	2.19
Pretax Income	-91.86	-101.88	-12.09	-3.22	-6.13
Earnings From Continuing Operations	-91.86	-101.88	-12.09	-3.22	-6.13
Earnings From Discontinued Operations	-	0	-	-	-
Net Income to Company	-91.86	-101.88	-12.09	-3.22	-6.13
Minority Interest in Earnings	0.02	0.02	-	-	-
Net Income	-91.83	-101.85	-12.09	-3.22	-6.13
Net Income to Common	-91.83	-101.85	-12.09	-3.22	-6.13
Shares Outstanding (Basic)	48	35	7	20	17
Shares Outstanding (Diluted)	48	35	7	20	17
Shares Change (YoY)	103.71%	381.26%	-62.79%	14.67%	-
EPS (Basic)	-1.91	-2.90	-1.66	-0.16	-0.36
EPS (Diluted)	-1.91	-2.90	-1.66	-0.16	-0.36
Free Cash Flow	-12.19	-28.38	-5.09	-0.24	-4.27
Free Cash Flow Per Share	-0.25	-0.81	-0.70	-0.01	-0.25
Gross Margin	70.27%	67.16%	-	-	-
Operating Margin	-573.26%	-2100.68%	-	-	-
Free Cash Flow Margin	-330.68%	-1908.24%	-	-	-
EBITDA	-20.58	-30.98	-10.2	-	-
D&A For EBITDA	0.56	0.26	0	-	-
EBIT	-21.14	-31.24	-10.2	-3	-7.92

Source: S&P Capital IQ. Standard template.